Get the Stockscreener App
15.98
1.11%
-0.18
After Hours:
16.39
0.41
+2.57%
Immunogen, Inc. (IMGN) current stock price is $15.98 with a 24-hour trading volume of 4.50M.
The stock decreased by -1.11% in the last 24 hours and rose by +6.53% in the past month.
Looking at the chart, IMGN stock price is below the pivot point level of $16.11, suggesting a potential bearish market, if it continues to fall close to the support level of $15.89, significant changes may happen.
Moreover, exploring the underlying reasons why IMGN is dropping is crucial for acquiring comprehensive view about the stock.
Immunogen, Inc. Stock (IMGN) Latest News
Wall Street Analysts Believe ImmunoGen (IMGN) Could Rally 52.99%: Here's is How to Trade
Zacks Investment Research
Are Options Traders Betting on a Big Move in ImmunoGen (IMGN) Stock?
Zacks Investment Research
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Zacks Investment Research
New Strong Buy Stocks for November 22nd
Zacks Investment Research
Where Immunogen Stands With Analysts
Benzinga
Best Momentum Stocks to Buy for November 16th
Zacks Investment Research
Immunogen, Inc. Stock (IMGN) Financials Data
Revenue
Net Income
Cash Flow
Earnings per Share
Immunogen, Inc. Stock (IMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Coen Stacy Ann | SVP & CHIEF BUSINESS OFFICER |
Nov 17 |
Option Exercise |
7.61 |
78,223 |
595,441 |
115,189 |
| Coen Stacy Ann | SVP & CHIEF BUSINESS OFFICER |
Nov 17 |
Sale |
16.05 |
78,223 |
1,255,479 |
36,966 |
| Coen Stacy Ann | SVP & CHIEF BUSINESS OFFICER |
Nov 16 |
Option Exercise |
5.53 |
4,100 |
22,665 |
41,066 |
| Coen Stacy Ann | SVP & CHIEF BUSINESS OFFICER |
Nov 16 |
Sale |
16.01 |
4,100 |
65,641 |
36,966 |
| Wingrove Theresa | SVP OF REGULATORY AFFAIRS |
Nov 15 |
Option Exercise |
4.55 |
166,725 |
758,599 |
169,536 |
| Coen Stacy Ann | SVP & CHIEF BUSINESS OFFICER |
Nov 15 |
Option Exercise |
5.48 |
26,286 |
144,008 |
63,252 |
| Wingrove Theresa | SVP OF REGULATORY AFFAIRS |
Nov 15 |
Sale |
15.85 |
166,725 |
2,642,591 |
2,811 |
| Coen Stacy Ann | SVP & CHIEF BUSINESS OFFICER |
Nov 15 |
Sale |
16.01 |
26,286 |
420,839 |
36,966 |
| Wingrove Theresa | SVP OF REGULATORY AFFAIRS |
Nov 07 |
Option Exercise |
10.65 |
19,517 |
207,856 |
22,328 |
| Wallace Richard John | Director |
Nov 07 |
Option Exercise |
14.70 |
10,000 |
147,000 |
10,000 |
About Immunogen, Inc.
ImmunoGen, Inc., a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Jazz Pharmaceuticals plc; and Debiopharm International SA. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
COMPANY PROFILE
NameImmunogen, Inc.
SectorHealthcare (1215)
IndustryBiotechnology (689)
Web
Phone781-895-0600
Employee293
Twitter
@immunogeninc
SEC filings
Latest SEC Filings
Address830 Winter Street, Waltham, MA, United States (2451)
1.03%
1.04%
Cap:
|
Volume (24h):